DBV Technologies S.A. (DBVT)
D
Pipeline Grade
Financial Position (from SEC Filings)
$229.2M
Cash & Equivalents
$49.1M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$844M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-01 | Phase3 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05741476 | Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age | PHASE3 | Active Not Recruiting | 600 |
| NCT07003919 | Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | PHASE3 | Recruiting | 480 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-29 | 8-K | DBV Technologies S.A. (DBVT, DBVTF) (CIK 0001613780) - EX-99.1 | EDGAR |